<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">

<!-- Mirrored from 127.0.0.1/novartis/references.html by HTTrack Website Copier/3.x [XR&CO'2010], Thu, 16 Jun 2011 01:42:06 GMT -->
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<title></title>
<link rel="stylesheet" type="text/css" href="css/style.css" media="screen" />
</head>

<body>

<div id="references-text1">
  <div id="reference-title">References:</div>
  <ol>
    <li><span>Vincenti F, Charpentier  B, Vanrenterghem Y, et al. A phase III study of belatacept-based  immunosuppression regimens versus cyclosporine in renal transplant recipients  (BENEFIT study). <em>Am J</em> <em>Transplant</em>.  2010;10(3):535-546.</span></li>
    <li><span>Durrbach A, Pestana JM,  Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney  transplants from extended criteria donors (BENEFIT-EXT study). <em>Am J</em> <em>Transplant</em>.  2010;10(3):547-557.</span></li>
    <li><span>Durrbach A, Francois H,  Beaudreuil S, et al. Advances in immunosuppression for renal transplantation. <em>Nat Rev Nephrol</em>. 2010;6(3):160-167.</span></li>
    <li><span>Organ transplant history.  The New York Organ Donor Network Web site.  http://www.donatelifeny.org/all-about-transplantation/organ-transplant-history.  Accessed May 5, 2011.</span></li>
    <li><span>Maxwell  RA, Eckhardt SB. <em>Drug Discovery: A  Casebook and Analysis.</em> Clifton, NJ: The Humana Press Inc.; 1990:95.</span></li>
    <li><span>Tribe  HT. The discovery and development of cyclosporin. <em>Mycologist</em>. 1998;12:20-22.</span></li>
    <li><span>Schuler W, Sedrani R, Cottens S, et al. SDZ  RAD, a new rapamycin derivative: pharmacological properties in vitro and in  vivo. <em>Transplantation</em>.  1997;64(1):36-42.</span></li>
    <li><span>US  Food and Drug Administration. Myfortic<sup>&reg;</sup> (mycophenolic acid)  Delayed-Release Tablets approval letter. NDA 50-791. 2004. http://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/50-791_Myfortic.cfm.  Accessed May 5, 2011.</span></li>
    <li><span>US Food and Drug  Administration. Zortress (everolimus) Tablets approval letter. NDA 21560. 2010.  http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021560s000_zortress_toc.cfm.  Accessed May 5, 2010.</span></li>
    <li><span>US Renal Data System. <i>USRDS 2009 Annual Data Report: Atlas of
Chronic Kidney Disease and End-Stage Renal Disease in the United States.</i> Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2009.  </span></li>
</ol>
</div>
<div id="references-text2">
<br/>
<ol START=11>
    <li><span>Vincenti  F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal  transplantation. <em>N Engl J  Med</em>. 2005;353(8):770-781.</span></li>
    <li><span>Data  on file. [US Transplant Market Final Presentation, March 17, 2010]. Novartis Pharmaceuticals Corp, East Hanover NJ.; 2010.</span></li>
    <li><span>Halloran  PF. Immunosuppressive drugs for kidney transplantation. <em>N Engl J Med</em>.  2004;351(26):2715-2729.</span></li>
    <li><span>Larsen  CP, Griny&oacute; J, Medina-Pestana J, et al. Belatacept-based regimens versus a  cyclosporine A-based regimen in kidney transplant recipients: 2-year results  from the BENEFIT and BENEFIT-EXT studies. <em>Transplantation</em>.  2010;90(12):1528-1535.</span></li>
    <li><span>Vincenti  F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT: a phase III  study of belatacept vs cyclosporine in kidney transplant recipients [ATC Abstract  227]. <em>Am J</em> <em>Transplant</em>. 2011;11(suppl 2):99.</span></li>
    <li><span>US  Food and Drug Administration. Belatacept (BMS-224818) FDA's Cardiovascular and Renal Drugs Advisory Committee briefing document  for March 2010 meeting. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM201859.pdf. Accessed May 5, 2011.</span></li>
    <li><span>Hirsch  HH. Polyomavirus BK nephropathy: a (re-)emerging complication in renal  transplantation. <em>Am J</em> <em>Transplant</em>.  2002;2(1):25-30.</span></li>
    <li><span>Medina  Pestana J, Grinyo J, Vanrenterghem Y, et al. Belatacept compared with  cyclosporine in renal allograft recipients of extended criteria donor kidneys:  3-year outcomes from the phase III BENEFIT-EXT trial [ATC Abstract 1088]. <em>Am J</em> <em>Transplant</em>.  2011;11(suppl 2):349.</span></li>
    <li><span>Larsen  C, Grinyo J, Medina Pestana J, et al. 3-year safety profile of belatacept in  kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies [ATC Abstract  228]. <em>Am J</em> <em>Transplant</em>. 2011;11(suppl 2):99-100.</span></li>
  </ol>
</div>
</body>

<!-- Mirrored from 127.0.0.1/novartis/references.html by HTTrack Website Copier/3.x [XR&CO'2010], Thu, 16 Jun 2011 01:42:06 GMT -->
</html>
